What is Doxil?
Doxil is a chemotherapy drug used in cancer treatment. It is a reformulated version of doxorubicin (Adriamycin®), a cancer drug that has been used for many years in traditional chemotherapy regimens, including VAD (vincristine, Adriamycin, and dexamethasone) in multiple myeloma.
In May 2007, Doxil was approved for use in combination with Velcade® (bortezomib, Takeda Oncology) to treat patients with myeloma who have not previously received Velcade and have received at least one prior therapy. Doxil is currently being evaluated in Phase III trials as a component of initial therapy for multiple myeloma.
Doxil is also known as doxorubicin HCl liposome injection or pegylated liposomal doxorubicin (PLD). It is distributed by Janssen Products, L.P. in the United States. Doxil was previously approved for the treatment of patients with ovarian cancer in 1999 and in patients with AIDS-related Kaposi’s sarcoma in 1995.